Ganciclovir CAS 82410-32-0 API BW 759 GCV Antiviral CMV Inhibitor High Quality

Ganciclovir (CAS 82410-32-0) belongs to the nucleoside antiviral drugs, being a kind of guanosine derivatives. Ganciclovir is a parenterally-active antiviral agent indicated for sight- or life-threatening cytomegalovirus (CMV) infections in immunocompromised patients. It has broad-spectrum, high-efficient inhibitory effects on herpes virus and is the first-choice drug for the treatment of cytomegalovirus infection with strong effect on hepatitis B virus and adenovirus as well. It is homologue of acyclovir (ACV) with its antiviral effect being similar as, but stronger than aciclovir, having especially strong inhibitory effects on cytomegalovirus associated with AIDS patients. It is clinical used for the treatment of induction phase and maintenance phase on immunocompromised patients (including AIDS patients) with concurrent cytomegalovirus retinitis. It can also be used for the prevention of cytomegalovirus disease for patients receiving organ transplantation or AIDS patients with positive results in cytomegalovirus serology test. 

Ganciclovir (CAS 82410-32-0) is a highly efficient, low-toxicity and high-selectivity virus inhibitor developed by the Syntex Company (United States). It is the first drug that has been approved by the US FDA for the treatment of cytomegalovirus (CMV) infection. Syntex has been granted of the exclusive right of production. In June 1988, this tablet has been approved for the first time to be listed in the UK, followed by being successively approved by France, the United States, Japan, and West Germany, Italy and Canada and other countries. Until the end of June 1999, it has been approved in more than 70 countries and regions for the prevention of immunodeficiency patients and the cytomegalovirus infection of patients of organ transplantation. In 2002, Ganciclovir tablets have obtained approval of the FDA, becoming available now.